US stock futures flounder amid tech weakness, Fed caution
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock has experienced a significant downturn, touching a 52-week low of $78.61, marking a stark contrast from its 52-week high of $173.25. According to InvestingPro data, the company maintains strong fundamentals with a current ratio of 4.2 and revenue growth of 53% in the last twelve months. This latest price level reflects a challenging period for the biotechnology firm, which has seen its shares decline by 18.31% over the past year. While investors remain cautious amid market complexities, analysts maintain a bullish consensus with price targets ranging from $75 to $215. The company’s expected net income growth and moderate debt levels suggest potential resilience. The 52-week low serves as a critical marker for Sarepta, as stakeholders assess the company’s strategic initiatives and potential for recovery in a volatile industry landscape. Discover more exclusive insights and 13 additional ProTips with an InvestingPro subscription.
In other recent news, Sarepta Therapeutics reported a fourth-quarter product revenue of $638.2 million, surpassing both Mizuho (NYSE:MFG)’s estimate of $575.3 million and the consensus estimate of $567 million. Despite this achievement, the company’s 2025 product sales guidance remains steady, with expectations between $2.9 billion and $3.1 billion. In light of these developments, Mizuho Securities adjusted its price target for Sarepta to $190, maintaining an Outperform rating. Similarly, RBC Capital Markets lowered its price target from $165 to $161, but also kept an Outperform rating, noting potential growth in Sarepta’s pipeline. Cantor Fitzgerald reaffirmed its Overweight rating with a $163 price target, updating its financial model to align with Sarepta’s guidance. Meanwhile, Scotiabank (TSX:BNS) initiated coverage with a Sector Perform rating and a $105 price target, expressing caution due to potential market challenges. Additionally, Sarepta recently faced a significant setback with the death of a patient linked to its gene therapy product, ELEVIDYS, due to acute liver failure. The company is actively investigating the incident and plans to update the therapy’s prescribing information.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.